• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RELX

    RELX PLC PLC

    Subscribe to $RELX
    $RELX
    Business Services
    Consumer Discretionary

    RELX PLC provides information-based analytics and decision tools for professional and business customers in North America, Europe, and internationally. It operates through four segments: Scientific, Technical & Medical; Risk; Legal; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics that help institutions and professionals to progress in science and advance healthcare. The Risk segment offers information-based analytics and decision tools that combine public and industry specific content with technology and algorithms to assist clients in evaluating and predicting risk. The Legal segment provides legal, regulatory, and business information and analytics that help customers in decision-making, as well as enhance the productivity. The Exhibitions segment is involved in the events business. The company was formerly known as Reed Elsevier PLC and changed its name to RELX PLC in July 2015. The company was incorporated in 1903 and is headquartered in London, the United Kingdom.

    IPO Year: 2015

    Exchange: NYSE

    Website: relx.com

    Recent Analyst Ratings for RELX PLC PLC

    DatePrice TargetRatingAnalyst
    3/26/2025Buy
    Goldman
    3/14/2025Equal Weight → Overweight
    Barclays
    1/8/2025Buy
    Redburn Atlantic
    3/1/2024Buy → Hold
    Berenberg
    10/4/2023Neutral → Buy
    Goldman
    9/27/2023Buy
    Berenberg
    1/31/2023Overweight → Equal Weight
    Barclays
    See more ratings